Search the Newsreel

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics reported its Q2 2026 financial results, highlighting steady execution across its pipeline. The company plans to initiate a Phase 1 study for PRT13722, a KAT6A degrader for HR+ breast cancer, in Q4 2026, and enrollment continues for its JAK2V617F inhibitor, PRT12396. Prelude …

Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear

Prelude Therapeutics (PRLD) stock rallied by 10.1% after its Q2 2026 earnings report showed a significant narrowing of losses, with revenue increasing from zero to US$5.70 million. While the company's financials appear cleaner due to collaborations, the article highlights that key 2026 clinical milestones, …

Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Prelude Therapeutics (NASDAQ:PRLD) announced its quarterly earnings, reporting an adjusted loss of $0.14 per share, surpassing analyst estimates by $0.03. The company also exceeded revenue expectations, achieving $5.70 million against a consensus of $4.78 million. Despite mixed analyst sentiment with a "Hold" consensus and …

Prelude Therapeutics 2Q Loss/Shr 14c >PRLD

Prelude Therapeutics reported a second-quarter loss per share of 14 cents. This financial update is significant for investors tracking PRLD.

Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash

Prelude Therapeutics announced its Q2 2026 financial results, reporting $5.7 million in revenue and a net loss of $13.9 million. The company holds $155.2 million in cash and equivalents, with a projected cash runway extending into Q2 2028. Key business highlights include progress in …

Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday

Prelude Therapeutics (PRLD) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.17 per share on revenue of $4.78 million. In the prior quarter, the company surpassed earnings estimates with a loss of …

Prologis, Inc. Announces Recommended Combination

Prologis, Inc. SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF …

Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and …

CoStar Data Shows Strong Prelet Activity Driving UK Lab Space Demand to a Record High

LONDON, August 06, 2026--(BUSINESS WIRE)--GSK's landmark life sciences prelet drove UK laboratory space demand to a new record,according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets. Rolling four-quarter take-up exceeded 1.2 million …

Prologis (PLD) Stock Looks Reasonable On Earnings But Stretched On Cash Flow

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. After a 34.1% one year return, Prologis no longer looks obviously cheap, and the …

Prologis says $18.8B takeover of Segro moving forward

Prologis announced Tuesday that it will move forward with a plan to acquire London-based logistics warehouse operator Segro. Prologis put forward its "best-and-final" offer last month, following multiple rejections from Segro's board. The final price tag values Segro at $18.8 billion. Prologis (NYSE: PLD) …

PROLOGIS ANNOUNCES PRICING OF COMMON STOCK OFFERING

SAN FRANCISCO, August 4, 2026 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) (the "Company" or "Prologis") announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock. The aggregate gross proceeds to the Company from the offering, before deducting estimated …

Prologis Announces Recommended Acquisition of SEGRO plc

Combination expands Prologis' European platform and enhances long-term growth opportunities SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) today announced that it has reached agreement with the board of SEGRO plc (LSE: SGRO) on the terms of a recommended acquisition of …

Wall Street Analysts Are Bullish on Top Healthcare Picks

This article highlights bullish sentiments from Wall Street analysts on three healthcare companies: Prelude Therapeutics (PRLD), Candel Therapeutics (CADL), and NeuroPace (NPCE). H.C. Wainwright analysts reiterated Buy ratings for all three, setting price targets of $8.00, $23.00, and $20.00 respectively. The article provides details …

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

PRLD|Prelude Therapeutics Inc|Price:4.520|Chg%:+0.130

This article provides a comprehensive stock analysis of Prelude Therapeutics Inc (PRLD) by TradingKey, highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, with a …

Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Prelude Therapeutics Inc (PRLD), assigning it a score of 6.29 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, but its operating efficiency is low. Key financial dimensions like …

PRLD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $8.00

HC Wainwright & Co. has reiterated a "Buy" rating for Prelude Therapeutics (PRLD) with an $8.00 price target, maintaining confidence despite the company's low GF Score™ of 22/100 and a high price-to-sales ratio suggesting overvaluation. The biotech firm specializes in precision oncology with a …

Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Prelude Therapeutics Inc (PRLD), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 1.12, ranking 326 out of 385 in the Biotechnology & Medical Research industry, and a beta value …

Prelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from HC Wainwright

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This article lists several health care stocks that experienced significant movement in Tuesday's pre-market session. It details both gainers, such as Gossamer Bio and Prelude Therapeutics, and losers, including Replimune Group and Nexalin Technology, along with their respective percentage changes and market capitalizations. The …

Prelude Therapeutics Inc (PRLD) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Prelude Therapeutics Inc (PRLD), covering operating, investing, and financing activities. It also includes frequently asked questions explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and …

Prelude Therapeutics Market Sentiment

This article provides an overview of the market sentiment for Prelude Therapeutics (PRLD), including analyst consensus, short interest, and recent analyst actions. Eight analysts currently rate PRLD as "Market Outperform," with an average price target of $5.00, suggesting a potential upside of 40.5%. The …

Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Prelude Therapeutics Inc (PRLD). It indicates that the company has not distributed any dividends over the past five years, with no data available for dividend dates. The article presents basic stock information …

PRLD|Prelude Therapeutics Inc|Price:3.830|Chg%:-0.100

Prelude Therapeutics Inc. (PRLD) is a clinical-stage oncology company focused on developing precision cancer medicines. The stock closed at $3.83, down 2.54%. Analysts have rated PRLD as a "Buy" with a target price of $8.00, suggesting a significant upside.

Prelude Therapeutics stock trades around recent lows as clinical pipeline spending weighs on results

Prelude Therapeutics, a clinical-stage oncology developer, is trading around recent lows due to significant research and development spending on its pipeline. The company reported zero revenue and a net loss of $112.1 million in 2023, funding its operations through $186.5 million in cash, cash …

British data centre owner set for £14bn US takeover

Segro owns Europe's biggest hub of data centres in Slough - Segro A British data centre owner is set to accept a £14bn takeover offer from an American suitor in the latest blow to the London stock market. Segro, which owns a significant hub …

Segro’s board will back Prologis’ $18.7B takeover bid

London-based logistics warehouse operator Segro has agreed to back an increased takeover bid from Prologis. The company's board acquiesced just hours after the San Francisco-based real estate investment trust upped its offer for the last time. Prologis (NYSE: PLD) put forward its "best-and-final" offer …

Prologis (PLD) Stock Looks Above Fair Value As 42% Run Cools

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. After a strong 41.8% 1 year return, Prologis now faces a valuation debate, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing …

Best and Final* Proposal and Request for PUSU Deadline Extension

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE …

Prologis (PLD) Could Be 4% Undervalued As Earnings Beat Lifts Guidance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Prologis (PLD) is back in focus after reporting second quarter 2026 results, along with …

Prologis Issues Update On Discussion Regarding Possible Combination With SEGRO

(RTTNews) - Prologis (PLD) stated that, following submission of latest proposal, its senior representatives met with SEGRO management. Prologis said the discussion did not provide meaningful clarity regarding the matters that would enable further progress. The SEGRO board rejected March 2024 Proposal in 72 …

Further Announcement Regarding a Possible Combination of SEGRO and Prologis

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE …